Comparison of Different Adjuvant Therapies for 9 Resectable Cancer Types

References

• . Bouche O, Ychou M, Burtin P, ; Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16(9):1488–1497
   PubMedGoogle Scholar
• . Hoover HC Jr, Brandhorst JS, Peters LC, . Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11(3):390–399
   PubMed Web of Science ®Google Scholar
• . Oettle H, Post S, Neuhaus P, . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–277
   PubMed Web of Science ®Google Scholar
• . Trimbos JB, Parmar M, Vergote I, ; InternationalCollaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105–112
   PubMed Web of Science ®Google Scholar
• . Winton T, Livingston R, Johnson D, ; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR. 10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–2597
   PubMed Web of Science ®Google Scholar
• . Baum M, Budzar AU, Cuzick J, ; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359(9324):2131–2139
   PubMed Web of Science ®Google Scholar
• . DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–58
   PubMed Web of Science ®Google Scholar
• . Nilsson B, Bumming P, Meis-Kindblom JM, . Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005;103(4):821–829
   PubMed Web of Science ®Google Scholar
• . DeMatteo RP, Ballman KV, Antonescu CR, ; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–1104
   PubMed Web of Science ®Google Scholar
• . Nilsson B, Sjölund K, Kindblom LG, . Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumors (GIST). Br J Cancer. 2007;96(11):1656–1658
   PubMed Web of Science ®Google Scholar
• . Joensuu H, Eriksson M, Sundby Hall K, . One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–1272
   PubMed Web of Science ®Google Scholar
• . Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728–1733
   PubMed Web of Science ®Google Scholar
• . Barratt A, Wyer PC, Hatala R, ; Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ. 2004;171(4):353–358
   PubMed Web of Science ®Google Scholar
• . Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492–1495
   PubMedGoogle Scholar
• . Bria E, Milella M, Gelibter A, . Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer. 2007;110(3):525–533
   PubMedGoogle Scholar
• . Loupakis F, Bria E, Vaccaro V, . Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res. 2010;29:58
   PubMedGoogle Scholar
• . Jani AB, Basil A, Heimann R, Hellman S. Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer. 2003;97(2):359–366
   PubMed Web of Science ®Google Scholar
• . Jani AB, Kao J, Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer. 2003;98(11):2351–2361
   PubMed Web of Science ®Google Scholar
• . Jani AB, Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis. Cancer. 2005;103(9):1833–1842
   PubMedGoogle Scholar
• . Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717
   PubMed Web of Science ®Google Scholar
• . Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419
   PubMed Web of Science ®Google Scholar
• . Jani AB. Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique. Cancer Invest. 2006;24(3):318–327
   PubMed Web of Science ®Google Scholar
• . Li J, Gong JF, Wu AW, Shen L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol. 2011;37(4):319–324
   PubMedGoogle Scholar
• . Clahsen PC, van de Velde CJ, Welvaart K, van Driel OJ, Sylvester RJ. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators. J Clin Oncol. 1995;13(1):33–41
   PubMedGoogle Scholar
• . Romond EH, Perez EA, Bryant J, . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684
   PubMed Web of Science ®Google Scholar
• . Ejlertsen B, Mouridsen HT, Jensen MB, ; Danish Breast Cancer Cooperative Group. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer. 2010;116(9):2081–2089
   PubMed Web of Science ®Google Scholar
• . Dufour P, Lang JM, Giron C, . Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9–12
   PubMedGoogle Scholar
• . Nitti D, Wils J, Sahmoud T, . Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer. 1997;33(8):1209–1215
   PubMedGoogle Scholar
• . Vaillant JC, Nordlinger B, Deuffic S, . Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231(4):449–456
   PubMed Web of Science ®Google Scholar
• . Schippinger W, Samonigg H, Schaberl-Moser R, ; Austrian Breast and Colorectal Cancer Study Group. A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97(8):1021–1027
   PubMedGoogle Scholar
• . Dahl O, Fluge O, Carlsen E, ; Norwegian Gastrointestinal Cancer Group. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol. 2009;48(3):368–376
   PubMed Web of Science ®Google Scholar
• . Lise M, Nitti D, Marchet A, . Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995;13(11):2757–2763
   PubMedGoogle Scholar
• . Cirera L, Balil A, Batiste-Alentorn E, . Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999;17(12):3810–3815
   PubMedGoogle Scholar
• . De Vita F, Giuliani F, Orditura M, ; Gruppo Oncologico Italia Meridionale. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 2007;18(8):1354–1358
   PubMedGoogle Scholar
• . Rosen HR, Jatzko G, Repse S, . Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol. 1998;16(8):2733–2738
   PubMedGoogle Scholar
• . Arriagada R, Bergman B, Dunant A, ; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360
   PubMed Web of Science ®Google Scholar
• . Felip E, Rosell R, Maestre JA, . Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(4):3138–3145
   PubMedGoogle Scholar
• . Pilepich MV, Caplan R, Byhardt RW, . Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol. 1997;15(3):1013–1021
   PubMed Web of Science ®Google Scholar
• . Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17
   PubMed Web of Science ®Google Scholar
• . Sondak VK, Liu PY, Tuthill RJ, . Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20(8):2058–2066
   PubMed Web of Science ®Google Scholar
• . Hancock BW, Wheatley K, Harris S, . Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53–61
   PubMedGoogle Scholar